Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk...

Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )

ASH 2020: Targeted therapies in r/r multiple myeloma

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar

ASH 2020: Targeted therapies in r/r multiple myeloma ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar )

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Prof Monica Bocchia - University of Siena, Siena, Italy

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve...

Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings ( Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA )

Treating acute leukaemias of ambiguous lineage

Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research...

Treating acute leukaemias of ambiguous lineage ( Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA )

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including...

Dr Shaji Kumar and Dr Wenming Chen

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective ( Dr Shaji Kumar and Dr Wenming Chen )

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the...

Dr Jorge Cortes - Augusta University, Augusta, USA

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D)...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin...

Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia

$Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )$

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil

Five year update of ECHELON-1 for classical Hodgkin lymphoma ( Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil )

More from ecancer